Publications

---

The publications listed below represent peer-reviewed studies that have utilised advanced human 3D cardiac organoid and engineered heart tissue systems aligned with the TrueCardium® cardiac New Approach Methodology (NAM) platform. Across regenerative biology, mitochondrial disease, ageing, hypertrophy, cardiac fibrosis, angiogenesis, infectious cardiology, and mechanistic cardiotoxicity research, these studies demonstrate the application of multicellular, vascularised, and functionally integrated human cardiac constructs for translational target validation, disease modelling, and predictive safety assessment.

Collectively, this body of work illustrates how TrueCardium®-aligned human cardiac NAM systems generate decision-grade, tissue-level data supporting mechanistic insight, therapeutic de-risking, and regulatory-relevant nonclinical evaluation.

1. Targeting miRNA-1a and miRNA-15b: A Novel Combinatorial Strategy to Drive Adult Cardiac Regeneration. Adv Sci (Weinh), e2414455 (2025).

Using advanced human 3D cardiac organoids, this study demonstrates that combinatorial modulation of miRNA-1a and miRNA-15b promotes cardiomyocyte cell-cycle re-entry and functional recovery in structured human myocardium. The multicellular platform mirrors the principles underpinning our [TrueCardium® regenerative disease modelling services], enabling translational validation of RNA-based therapeutics within physiologically integrated human cardiac tissue.

2. Human heart organoids reveal a regenerative strategy for mitochondrial disease. bioRxiv, 

2025.2012.2018.695153 (2025).

Vascularised human heart organoids were used to model mitochondrial cardiomyopathy in a clinically relevant 3D setting, integrating structural, functional, and transcriptomic readouts. This work exemplifies the translational capabilities of [TrueCardium® human cardiac organoid platforms] for disease modelling, target validation, and therapeutic screening in complex metabolic cardiomyopathies.

3. Aging impairs the neurovascular interface in the heart. Science (New York, N.Y 381, 897-906 (2023).

Human 3D cardiac tissue models revealed age-associated disruption of neurovascular coupling within the myocardium. Multicellular organoid systems, aligned with [TrueCardium® vascularised and innervated cardiac constructs], enabled mechanistic interrogation of endothelial–neuronal cross-talk, supporting predictive modelling of age-related cardiac dysfunction and microvascular decline.

4. The lncRNA Sweetheart regulates compensatory cardiac hypertrophy after myocardial injury in murine males. Nature Communications 14, 7024 (2023).

Human engineered 3D cardiac tissues were used to validate the role of the lncRNA Sweetheart in hypertrophic remodelling. By bridging molecular findings to contractile tissue phenotypes, this study reflects the translational workflow implemented in [TrueCardium® hypertrophy and remodelling models], supporting target de-risking in human-relevant cardiac systems.

5. The endothelial-enriched lncRNA LINC00607 mediates angiogenic function. Basic Research in Cardiology 118, 5 (2023). 

Using human vascularised 3D cardiac constructs, this study identifies LINC00607 as a regulator of endothelial angiogenic activity within integrated cardiac tissue. The work demonstrates how multicellular heart models—comparable to [TrueCardium® vascularised cardiac organoids]—enable predictive assessment of endothelial–cardiomyocyte cross-talk and angiogenic pathway modulation.

6. A human cell atlas of the pressure-induced hypertrophic heart. Nature Cardiovascular Research 1, 174-185 (2022). 

By integrating single-cell profiling with functional 3D cardiac tissue systems, this study maps the cellular architecture of pressure-induced hypertrophy. Human organoid-based validation parallels the systems-level approach of [TrueCardium® translational hypertrophy models], facilitating mechanistic insight and regulatory-aligned preclinical evaluation.

7. Novel SARS-CoV-2 variants induce higher toxicity in cardiovascular cells. European Heart Journal 42 (2021).

Human cardiomyocyte-containing 3D cardiac tissues were used to compare the cardiovascular toxicity of emerging SARS-CoV-2 variants. This work underscores the importance of human organoid platforms—such as [TrueCardium® predictive cardiotoxicity testing services]—for variant-specific safety assessment and translational infectious cardiology research.

8. Mitochondrial–cell cycle cross-talk drives endoreplication in heart disease. Science Translational Medicine 13 (2021).

Human 3D cardiac tissue systems revealed mitochondrial signalling pathways driving cardiomyocyte endoreplication in disease. The study exemplifies how multicellular cardiac organoids, consistent with [TrueCardium® mechanistic disease modelling services], enable integrated metabolic and functional analysis for translational target discovery.

9. Dissection of heterocellular cross-talk in vascularized cardiac tissue mimetics. Journal of Molecular and Cellular Cardiology138, 269-282 (2020). 

Vascularised 3D cardiac tissue mimetics were developed to dissect heterocellular communication between cardiomyocytes, endothelial cells, and stromal populations. This foundational work supports the architecture implemented in [TrueCardium® multicellular cardiac organoid systems], enabling predictive modelling of tissue-level signalling and therapeutic modulation.

10. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovascular Research 116, 2207-2215 (2020). 

Human cardiomyocyte-based 3D culture systems demonstrated direct SARS-CoV-2 infection and cytotoxicity in cardiac tissue. The study highlights the translational relevance of human heart models, aligned with [TrueCardium® human-relevant cardiotoxicity screening platforms], for evaluating viral tropism, contractile dysfunction, and compound safety in preclinical development.